辉瑞与Nodality合作简化自身免疫性疾病药物开发

Pharmadeals Review Pub Date : 2012-08-15 DOI:10.3833/PDR.V2012I8.1790

Heather Cartwright

{"title":"辉瑞与Nodality合作简化自身免疫性疾病药物开发","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I8.1790","DOIUrl":null,"url":null,"abstract":"Pfizer has formed a multiyear collaboration with Nodality to use the latter’s single cell network profiling (SCNP) technology as a tool to streamline the development of new compounds for autoimmune diseases, beginning with lupus. Pfizer also has the option to use Nodality's technology, which was licensed from Stanford University, to develop novel companion diagnostics. Pfizer Venture Investments has been an investor in Nodality since 2008.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"16 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pfizer Collaborates with Nodality to Streamline Autoimmune Disease Drug Development\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I8.1790\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pfizer has formed a multiyear collaboration with Nodality to use the latter’s single cell network profiling (SCNP) technology as a tool to streamline the development of new compounds for autoimmune diseases, beginning with lupus. Pfizer also has the option to use Nodality's technology, which was licensed from Stanford University, to develop novel companion diagnostics. Pfizer Venture Investments has been an investor in Nodality since 2008.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"16 2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-08-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I8.1790\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I8.1790","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

辉瑞与Nodality达成多年合作，利用后者的单细胞网络分析(SCNP)技术，简化自身免疫性疾病新化合物的开发，首先是狼疮。辉瑞还可以选择使用Nodality的技术，该技术是从斯坦福大学获得许可的，用于开发新的伴随诊断。Pfizer Venture Investments自2008年以来一直是Nodality的投资者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Pfizer Collaborates with Nodality to Streamline Autoimmune Disease Drug Development

Pfizer has formed a multiyear collaboration with Nodality to use the latter’s single cell network profiling (SCNP) technology as a tool to streamline the development of new compounds for autoimmune diseases, beginning with lupus. Pfizer also has the option to use Nodality's technology, which was licensed from Stanford University, to develop novel companion diagnostics. Pfizer Venture Investments has been an investor in Nodality since 2008.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmadeals Review

自引率

0.00%

发文量